Compare Amphastar Pharmaceuticals Inc (AMPH) vs Comcast Corporation (CMCSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Comcast Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Comcast Corporation trades at $25.58 (market cap $89.43B). The key difference: Comcast Corporation is far larger — about 103.5× Amphastar Pharmaceuticals Inc's market cap, and Comcast Corporation pays a 5.24% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CMCSA | |
|---|---|---|
Market Cap | $863.95M | $89.43B |
Sector | Health | Media |
52-Week High | $30.81 | $32.50 |
52-Week Low | $16.87 | $21.92 |
Enterprise Value | $1.26B | $172.15B |
Dividend Yield | — | 5.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Comcast (CMCSA) trades at $25.36, up 0.75% today, with strong technical momentum showing bullish moving averages and support at $25. The company demonstrates robust fundamentals with a low P/E of 8.13 and consistent earnings beats, including Q2 2026 EPS of $1.04 versus $0.97 expected. Recent expansion announcements in Florida and New Hampshire highlight ongoing growth initiatives.
CMCSA presents compelling value with discounted valuation multiples and a 55.74% analyst buy rating. Key opportunities include wireless growth and Peacock profitability, while risks involve competitive pressures and the planned NBCUniversal spinoff. The consensus price target of $27.78 suggests 9.5% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →
